Trial Profile

Escitalopram for Agitation in Alzheimer's Disease

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary)
Indications Alzheimer's disease; Dementia
Focus Therapeutic Use
Acronyms S-CitAD

Most Recent Events

01 May 2025 Results assessing the efficacy and safety of escitalopram in treating agitation in AD after failure of a psychosocial intervention (PSI), published in the Nature Medicine.
01 Aug 2024 Trial design presented at the Alzheimer's Association International Conference 2024
01 Aug 2024 According to Trial design presented at the Alzheimer's Association International Conference 2024, last participant will complete the study in late winter and mask will be broken in March 2024. Outcomes will be first presented at the AAIC meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com